Search Results
Mar 26, 2026, 08:31 ET MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update
peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In
More news about: MetaVia Inc.
Mar 26, 2026, 08:00 ET Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
rapidly in recent years, with most focused on GLP-1 receptor agonists, which are associated with both fat and lean mass loss, gastrointestinal side effects, and a rapid "rebound" weight regain following discontinuation. Unlike GLP-1 receptor agonists that focus on weight reduction
More news about: Pulmatrix Inc.
Mar 26, 2026, 07:05 ET Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735
rates among VK2735 cohorts were well-balanced compared with placebo.About GLP-1 and Dual GLP-1/GIP AgonistsActivation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body weight, and improve
More news about: Viking Therapeutics, Inc.
Mar 26, 2026, 06:00 ET Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham
GLP-1 receptor agonist use. In Zenkuda-treated patients, the proportion achieving a ≥2-step improvement in DRSS was 60.0% among those using GLP-1 medications versus 64.3% among those not using GLP-1 medications, supporting
More news about: Kodiak Sciences Inc.
Mar 26, 2026, 06:00 ET Innovent Announces 2025 Annual Results and Business Updates
(Teprotumumab, IGF-1R antibody), China's first innovative therapy for thyroid eye disease in 70 years; Mazdutide, the world's first and only approved GCG/GLP-1 dual-receptor agonist for obesity and type 2 diabetes; and SINTBILO® (tafolecimab injection), the first China-domestic PCSK9 inhibitor
More news about: Innovent Biologics
Mar 26, 2026, 04:00 ET Allergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress (AMWC)
up to 18 months. Subgroup analyses also suggest potential benefits in patients undergoing medical weight loss, including those treated with GLP-1 therapies.Key Findings:HA-CaHA injectables were shown to improve skin quality, including elasticity, firmness,
More news about: AbbVie
Mar 25, 2026, 08:00 ET Kalohexis Announces Publication in Frontiers in Endocrinology Defining Design Criteria for Next-Generation Melanocortin Drugs for General Obesity
therapeutic window and a body composition profile that compares favorably to GLP-1 therapies. Our analysis highlights the promise of emerging melanocortin therapeutics both as monotherapies and as GLP-1 adjuvants for general obesity," Dr. Marks continued. Kalohexis was recently
More news about: Kalohexis
Mar 25, 2026, 02:32 ET BrightGene Announces Positive Topline Phase 1 Results of Oral BGM0504 in Obesity in China and the United States
"BrightGene" or "the Company") today announced positive topline results from Phase 1 clinical studies of BGM0504, an investigational oral GLP-1/GIP dual receptor agonist, in adult participants in China and the United States, including healthy volunteers and individuals with overweight or obesity.
More news about: BrightGene
Mar 24, 2026, 11:27 ET Louisiana Jail Sees 62% Reduction in Infection Complaints Within 30 Days of Disinfectant Switch
disinfectant is engineered to exceed healthcare-grade disinfection benchmarks with a one-step, one-minute contact time, as demonstrated in independent, EPA GLP-compliant laboratory testing, and is designed for safe use in occupied environments."We're acutely aware of the risks associated with certain
More news about: ArrowClean
Mar 24, 2026, 11:11 ET Pendulum Therapeutics Launches Superfood Gut Fuel Powder
Doctor-Formulated Fiber and Polyphenols to Fuel the Gut Microbiome, Support Healthy Blood Sugar Levels, and Nourish GLP-1 Boosting Bacteria SAN FRANCISCO, March 24, 2026 /PRNewswire/
More news about: Pendulum Therapeutics
Mar 24, 2026, 11:05 ET Anti-Aging Protein Research Takes a Step Forward with Cell Cloning
cardiovascular intervention that could reshape metabolic disease treatment.Altimmune (NASDAQ: ALT) is advancing pemvidutide, a GLP-1/glucagon dual receptor agonist for metabolic disease that targets the $65 billion metabolic syndrome opportunity through hormonal regulation of fat metabolism.
More news about: Equity Insider
Mar 24, 2026, 10:47 ET Fosun Pharma Announces 2025 Annual Results
US$260 million in the whole year, with potential milestone payments exceeding US$ 3.8 billion. Among them, the global licensing project of the GLP-1 target YP05002 garnered an upfront payment of US$150 million and potential total payments of US$2.085 billion, fully confirming the global competitiveness
More news about: Fosun Pharma
Mar 24, 2026, 09:02 ET Phenomix Sciences Report Finds Patients See GLP-1s as Progress, Not a Cure; Want More Guidance on Long-Term Care
survey shows patient expectations and perceptions of GLP-1s are evolving, and clearereducation is shaping obesity treatment decisions.GLP-1s are viewed as progress, not a cure: Most patients (54%) see GLP-1s as a meaningful step forward while recognizing obesity
More news about: Phenomix Sciences
Mar 24, 2026, 08:42 ET Clean Eatz Kitchen Publishes 2026 Prepared Meal Delivery Industry Report Comparing Seven National Services on Price, Nutrition, and Flexibility
Kitchen offers chef-prepared, dietitian-designed frozen meals shipped nationwide. Meal plans include Weight Loss, High Protein, Gluten-Free, GLP-1, and Build Your Own, starting at $7.50 per meal. No subscriptions required. Free shipping over $85. More at
More news about: CE Kitchen Inc
Mar 24, 2026, 08:30 ET Accelerating GLP-1 Peptides to Market Through Integrated Formulation & Analytical Development, Upcoming Webinar Hosted by Xtalks
TORONTO, March 24, 2026 /PRNewswire/ -- GLP-1 peptide therapeutics are rapidly reshaping the treatment landscape for diabetes and obesity, creating increased demand for robust formulation
More news about: Xtalks
Mar 23, 2026, 14:26 ET Galderma reúne profissionais injetores para apresentar as últimas tendências em estética injetável
novas tendências de mercado, a Galderma também aprofundará a discussão sobre a relação entre a perda de peso, especialmente a induzida por análogos de GLP-1, e seus impactos na aparência do rosto.Um estudo36 recente da companhia, conduzido com mais de 1.000 usuários desses medicamentos
More news about: Galderma
Mar 23, 2026, 09:25 ET Solvias Earns EcoVadis Bronze Medal, Ranking in Top 35% of Companies for Sustainability Performance
product release.Headquartered near Basel, Switzerland, Solvias operates five global Centers of Excellence, all adhering to the highest ISO, GMP, GLP, and FDA standards.Learn more at
More news about: Solvias
Mar 23, 2026, 09:25 ET Solvias Earns EcoVadis Bronze Medal, Ranking in Top 35% of Companies for Sustainability Performance
product release.Headquartered near Basel, Switzerland, Solvias operates five global Centers of Excellence, all adhering to the highest ISO, GMP, GLP, and FDA standards.Learn more at
More news about: Solvias
Mar 23, 2026, 09:25 ET Solvias erhält die EcoVadis-Bronzemedaille und gehört damit zu den 35% der Unternehmen mit der besten Nachhaltigkeitsleistung
Arzneimitteln.Solvias hat seinen Hauptsitz in der Nähe von Basel, Schweiz, und betreibt fünf globale Kompetenzzentren, die alle die höchsten ISO-, GMP-, GLP- und FDA-Standards einhalten.Weitere Informationen unter
More news about: Solvias
Mar 23, 2026, 09:25 ET Solvias ontvangt een bronzen medaille van EcoVadis en behoort daarmee tot de top 35% van bedrijven op het gebied van duurzaamheidsprestaties
geneesmiddelen.Solvias, met hoofdkantoor nabij Basel in Zwitserland, beschikt over vijf wereldwijde Centers of Excellence, die allemaal voldoen aan de hoogste ISO-, GMP-, GLP- en FDA-normen.Meer informatie op
More news about: Solvias
Mar 23, 2026, 09:25 ET Solvias reçoit la médaille de bronze d'EcoVadis et se classe parmi les 35 % d'entreprises les plus performantes en matière de développement durable
pharmaceutiques.Solvias, dont le siège est situé près de Bâle, en Suisse, exploite cinq centres d'excellence mondiaux, tous conformes aux normes ISO, GMP, GLP et FDA les plus strictes.Pour en savoir plus :
More news about: Solvias
Mar 23, 2026, 09:04 ET 28bio's Endurance Study Meets Primary Endpoint, Showing CNS-3D Brain Organoids Predict Clinical Seizure Liability
development."CNS toxicity accounts for approximately 25%2 of failures across drug discovery and development, yet it is rarely detected during GLP toxicology studies, highlighting the limitations of animal models in predicting human neurological effects."FDA and NIH have both emphasized the
More news about: 28bio
Mar 23, 2026, 07:30 ET EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis
toxicity. In preclinical studies, ENDO-205 demonstrated elimination of endometriosis lesions and associated inflammation, with no safety signals observed in GLP toxicology studies.The program has been supported by multiple NIH awards from the Eunice Kennedy Shriver National Institute of Child Health
More news about: EndoCyclic Therapeutics
Mar 22, 2026, 20:00 ET Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study
innovative programs, including IBI3011, an IL-1RAP monoclonal antibody designed to control acute gout flares, as well as mazdutide, a globally innovative GCG/GLP-1 dual receptor agonist that may provide therapeutic benefits for patients with obesity complicated by hyperuricemia. By building a product portfolio
More news about: Innovent Biologics
Mar 20, 2026, 09:01 ET 2026 Survey Reveals AI Dominates Focus for HR Executives as Uncertainty Abounds
Specialty drugs.GLP-1 coverage is expanding cautiously.GLP-1 medications for weight loss and obesity management have become a major focus for employer-sponsored plans. More than half of organizations (59%) report covering GLP-1s for weight loss with specific
More news about: CHRO Association